drugset / Trial / NCT03405870

LIPIDS-P Trial Phase I/II Trial

NCT03405870

Phase 1/2 Completed 59 enrolled University of Florida
RandomizedParallel-groupSingle-blindTreatment

Summary

Briefly, this pilot clinical trial will evaluate preliminary safety and efficacy of the study drug (Smoflipid) at elevating cholesterol levels (primary outcome) in patients with sepsis and moderate organ dysfunction and will also evaluate measures of organ dysfunction, mortality, and biological activity (secondary outcomes).

Timeline

Start
2018-08-17
Primary completion
2023-04-26
Completion
2023-04-26

Drugs

EvaluationDrugModalityDoseRoute
Subject SMOFlipid Other / unclassified 1 g/kg Intravenous
Subject SMOFlipid Other / unclassified 1.2 g/kg Intravenous
Subject SMOFlipid Other / unclassified 1.4 g/kg Intravenous
Subject SMOFlipid Other / unclassified 1.6 g/kg Intravenous